Filtered By:
Condition: Thrombocytopenia

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 366 results found since Jan 2013.

Platelet count as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia
Conclusions: The evolution of circulating PC between admission and early stage evolution is related to higher risk of MACE in CAP patients during the post-episode year. Furthering the study of platelets and their activation could be useful as prognostic biomarkers in order to strengthen the prevention of long-term cardiovascular events.
Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Luquero-Bueno, S., Galvan-Roman, J. M., Curbelo, J., Lancho-Sanchez, A., Roy-Vallejo, E., Ortega-Gomez, M., Gomez, M., Mateo-Jimenez, G., Manzaneque-Pradales, M., Aspa Marco, J. Tags: Respiratory infections Source Type: research

Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis from Four Post-Approval Studies.
Conclusions: Compared to the non-HBR population, HBR patients experienced worse 4-year outcomes after PCI with CoCr everolimus-eluting stent. Both CTE and MB had a significant impact on subsequent risk of mortality irrespective of bleeding risk. PMID: 31992063 [PubMed - as supplied by publisher]
Source: Circulation - January 28, 2020 Category: Cardiology Authors: Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U, Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R Tags: Circulation Source Type: research

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis
In this meta-analysis, we aimed to systematically compare the post percutaneous coronary interventional (PCI) adverse bleeding events, stent thrombosis, stroke and other cardiovascular outcomes in a population...
Source: BMC Clinical Pharmacology - April 25, 2020 Category: Drugs & Pharmacology Authors: Manyun Long, Ziliang Ye, Jing Zheng, Wuxian Chen and Lang Li Tags: Research article Source Type: research

Heparin-Induced Thrombocytopenia after Total Knee Replacement.
Authors: Salášek M, Šlechtová J, Pavelk T Abstract Heparin-induced thrombocytopenia is a rare complication of treatment with both unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Antibodies against the complex heparin-platelet factor 4 are the main cause of pathogenesis, resulting in the activation of thrombocytes, coagulation, endothelium, monocytes, neutrophils and subsequent highly prothrombotic state. The prothrombotic state can result not only in venous but also in arterial thrombosis at different locations (which is manifested apart from venous thromboembolic disease also by acute lim...
Source: Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca - May 13, 2020 Category: Orthopaedics Tags: Acta Chir Orthop Traumatol Cech Source Type: research

Outcomes of left ventricular assist device implantation in hypercoagulable patients
ConclusionsIn this series, positive laboratory tests for hypercoagulability were common amongst patients undergoing LVAD implantation although few had positive clinical histories. Survival and freedom from thromboembolic complications were comparable to non ‐hypercoagulable patients. Hypercoagulability alone should therefore not serve as a contraindication to LVAD implantation.
Source: Journal of Cardiac Surgery - July 26, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Keith A. Dufendach, Laura Seese, Blaise Stearns, Gavin Hickey, Michael Mathier, Mary Keebler, Shangzhen Chen, Christopher M. Sciortino, Floyd W. Thoma, Arman Kilic Tags: ORIGINAL ARTICLE Source Type: research

Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.
CONCLUSION: Daratumumab is associated with lower risk of VTE in clinical trials. PMID: 32710431 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - July 23, 2020 Category: Hematology Authors: Wang J, Kim Y Tags: Int J Hematol Source Type: research

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

Updated understanding of platelets in thrombosis and hemostasis: the roles of integrin PSI domains and their potential as therapeutic targets.
Authors: MacKeigan DT, Ni T, Shen C, Stratton TW, Ma W, Zhu G, Bhoria P, Ni H Abstract Platelets are small blood cells known primarily for their ability to adhere and aggregate at injured vessels to arrest bleeding. However, when triggered under pathological conditions, the same adaptive mechanism of platelet adhesion and aggregation may cause thrombosis, a primary cause of heart attack and stroke. Over recent decades, research has made considerable progress in uncovering the intricate and dynamic interactions that regulate these processes. Integrins are heterodimeric cell surface receptors expressed on all metazoa...
Source: Cardiovascular and Hematological Disorders Drug Targets - October 3, 2020 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Thrombocytopenia-Related Problems in Patients with Concomitant Atrial Fibrillation Requiring Antithrombotic Prevention: A Retrospective Cohort Study
Resumo Baixas doses de edoxabana e enoxaparina s ódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, a valiou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p< 0,05 foi considerado es...
Source: Arquivos Brasileiros de Cardiologia - October 23, 2020 Category: Cardiology Source Type: research

Temporal Evolution of the iFR (Instantaneous Wave-Free Ratio) Employment Results Analysis
Resumo Baixas doses de edoxabana e enoxaparina s ódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, a valiou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p< 0,05 foi considerado es...
Source: Arquivos Brasileiros de Cardiologia - October 23, 2020 Category: Cardiology Source Type: research

Update of the Brazilian Guidelines for Valvular Heart Disease – 2020
Resumo Baixas doses de edoxabana e enoxaparina s ódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, a valiou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p< 0,05 foi considerado es...
Source: Arquivos Brasileiros de Cardiologia - October 23, 2020 Category: Cardiology Source Type: research

Statement – Protocol for the Reconnection of Cardiology Services with Patients During the COVID-19 Pandemic – 2020
Resumo Baixas doses de edoxabana e enoxaparina s ódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, a valiou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p< 0,05 foi considerado es...
Source: Arquivos Brasileiros de Cardiologia - October 23, 2020 Category: Cardiology Source Type: research

Erratum
Resumo Baixas doses de edoxabana e enoxaparina s ódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, a valiou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p< 0,05 foi considerado es...
Source: Arquivos Brasileiros de Cardiologia - October 23, 2020 Category: Cardiology Source Type: research

Safety of Temporary Interruption of Antiplatelet Therapy in Dengue Fever with Thrombocytopenia
Dengue fever, caused by a flavivirus transmitted by Aedes mosquitoes, is endemic in more than 100 countries with 2.5 billion people at risk.1 With climate change and globalization causing geographical expansion of Aedes mosquitoes, increased exposure especially in dengue-na ïve populations is predicted.2,3 Thrombocytopenia commonly occurs with dengue 4 and may be associated with bleeding. Avoidance of intramuscular injections, bed rest and measures to reduce risk of falls are usually advised. Increasingly, dengue occurs in older adults,5–7 and adult patients with de ngue fever may have comorbidities such as ischemic hea...
Source: Journal of Infection - November 30, 2020 Category: Infectious Diseases Authors: Po Ying Chia, Htet Lin Htun, Yee Sin Leo, David Chien Lye Source Type: research

Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism
In this study, we aimed to uncover the genetic basis of the above conditions by examining genome-wide associations and tissue-specific gene expression to build a molecular network. Based on gene ontology, we annotated various SNPs with five ancestral terms: pulmonary embolism, venous thromboembolism, vascular diseases, cerebrovascular disorders, and stroke. The gene-gene interaction network revealed three clusters that each contained hallmark genes for D-dimer/fibrinogen levels, homocysteine levels, and arterial/venous thromboembolism with F2 and F5 acting as connecting nodes. We propose that genotyping COVID-19 patients f...
Source: Frontiers in Pharmacology - December 9, 2020 Category: Drugs & Pharmacology Source Type: research